APA (7th ed.) Citation

Ingram, M. A., Lauren, B. N., Pumpalova, Y., Park, J., Lim, F., Bates, S. E., . . . Hur, C. (2022, September). Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Reports.

Chicago Style (17th ed.) Citation

Ingram, Myles A., et al. "Cost‐effectiveness of Neoadjuvant FOLFIRINOX Versus Gemcitabine Plus Nab‐paclitaxel in Borderline Resectable/locally Advanced Pancreatic Cancer Patients." Cancer Reports Sep. 2022.

MLA (9th ed.) Citation

Ingram, Myles A., et al. "Cost‐effectiveness of Neoadjuvant FOLFIRINOX Versus Gemcitabine Plus Nab‐paclitaxel in Borderline Resectable/locally Advanced Pancreatic Cancer Patients." Cancer Reports, Sep. 2022.